Metrics as of 10/17/2026, 09:31 AM (Berlin time), refresh in progress.
ProQR Therapeutics Stock
ProQR Therapeutics N.V.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- CEO
- Daniel Anton de Boer
- Employees
- 166
- Market cap
- $181 M
- IPO
- 18/09/2014
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known…
ProQR Therapeutics stock: price history
1D
-9.7%
1W
-19.6%
1M
-29.6%
6M
-34.2%
YTD
-35.1%
1Y
-53.2%
2Y
-67.4%
5Y
-83.4%
10Y
-79.4%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~3% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about ProQR Therapeutics
Analyst assessment of ProQR Therapeutics
PRICE TARGET LOW
US$3.00
CONSENSUS
US$3.00
MEDIAN
US$3.00
PRICE TARGET HIGH
US$3.00
1
STRONG BUY
10
BUY
1
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 01/10/2026
ProQR Therapeutics stock metrics
P/E
-2.94
P/B
1.61
EV/EBITDA
-1.51
RETURN ON EQUITY
-11.2%
NET MARGIN
-99.6%
DEBT/EQUITY
0.17
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
66.2%
FLOAT SHARES
91,443,894
AVG. DAILY VOLUME (30D)
747,225
Insider transactions (SEC)
de Boer Daniel Anton
Filius Bart
de Boer Daniel Anton
de Boer Daniel Anton
Filius Bart
Institutional holders
Comparable stocks
Frequently asked questions about ProQR Therapeutics stock
What does ProQR Therapeutics do?
ProQR Therapeutics N.V. is a company in the Healthcare sector, Biotechnology industry, headquartered in Netherlands.
The CEO is Daniel Anton de Boer, the company employs around 166 people.
The IPO was on 18/09/2014; the stock trades on NASDAQ under the ticker PRQR.
What do analysts say about ProQR Therapeutics stock?
12 analysts rate the stock, the consensus is Buy (as of 01/10/2026).
The average price target is US$3.00, ranging from US$3.00 to US$3.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
When does ProQR Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -3% stronger than usual.
Does ProQR Therapeutics pay a dividend?
No, ProQR Therapeutics currently does not pay a dividend.
Which stocks are comparable to ProQR Therapeutics?
Comparable stocks include argenx, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get ProQR Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess ProQR Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.